Paroxysmal Sympathetic Hyperactivity in Severe Anti-N-Methyl-d-Aspartate Receptor Encephalitis: A Single Center Retrospective Observational Study.
anti-NMDA receptor encephalitis
autonomic dysfunction
neuro-intensive care unit
paroxysmal sympathetic hyperactivity
treatment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
02
2021
accepted:
12
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Paroxysmal sympathetic hyperactivity (PSH) is a disorder with excessive sympathetic activity commonly recognized in patients with acquired brain injury. Autonomic instability is frequent in anti-N-methyl-d-aspartate receptor encephalitis (anti-NMDARE). However, PSH in anti-NMDARE has gained little attention. We retrospectively reviewed 24 patients diagnosed with severe anti-NMDARE in the neuro-intensive care unit (NICU) between 2014 and 2019. Patients were assessed with the PSH assessment measure (PSH-AM) scale, and categorized into "PSH+" group and "PSH-" group. The clinical characteristics, hospital mortality, and functional outcome by modified Rankin Scale (mRS) score at six months after discharge were compared between the two groups. Among patients with PSH+, the clinical features and pharmacotherapy of PSH were summarized and compared. Twenty-four patients were included in the study. Twelve of them (50%) were categorized as PSH+ based on PSH-AM scores. There were no significant differences in the demographic characteristic, GCS scores upon admission, incidence of status epilepticus, teratoma occurrence, hospital mortality, and 6-month mRS between PSH+ and PSH- groups. Patients with PSH+ had increased length of NICU stay, hospital stay and duration of mechanical ventilation. The most prominent clinical features of PSH in severe anti-NMDARE were tachycardia and hyperthermia, while posturing was the relatively mildest clinical feature. Propranolol and clonazepam were more commonly used than gabapentin in pharmacotherapy of PSH in severe anti-NMDARE. The incidence of PSH in severe anti-NMDARE patients was as high as 50%. Patients with PSH demonstrated prolonged NICU stay, hospital stay and increased duration of mechanical ventilation, while no effect on hospital mortality and functional outcome. Clinicians should be aware of the distinctive characteristics and treatment options of PSH in severe anti-NMDARE.
Sections du résumé
Background
Paroxysmal sympathetic hyperactivity (PSH) is a disorder with excessive sympathetic activity commonly recognized in patients with acquired brain injury. Autonomic instability is frequent in anti-N-methyl-d-aspartate receptor encephalitis (anti-NMDARE). However, PSH in anti-NMDARE has gained little attention.
Methods
We retrospectively reviewed 24 patients diagnosed with severe anti-NMDARE in the neuro-intensive care unit (NICU) between 2014 and 2019. Patients were assessed with the PSH assessment measure (PSH-AM) scale, and categorized into "PSH+" group and "PSH-" group. The clinical characteristics, hospital mortality, and functional outcome by modified Rankin Scale (mRS) score at six months after discharge were compared between the two groups. Among patients with PSH+, the clinical features and pharmacotherapy of PSH were summarized and compared.
Results
Twenty-four patients were included in the study. Twelve of them (50%) were categorized as PSH+ based on PSH-AM scores. There were no significant differences in the demographic characteristic, GCS scores upon admission, incidence of status epilepticus, teratoma occurrence, hospital mortality, and 6-month mRS between PSH+ and PSH- groups. Patients with PSH+ had increased length of NICU stay, hospital stay and duration of mechanical ventilation. The most prominent clinical features of PSH in severe anti-NMDARE were tachycardia and hyperthermia, while posturing was the relatively mildest clinical feature. Propranolol and clonazepam were more commonly used than gabapentin in pharmacotherapy of PSH in severe anti-NMDARE.
Conclusions
The incidence of PSH in severe anti-NMDARE patients was as high as 50%. Patients with PSH demonstrated prolonged NICU stay, hospital stay and increased duration of mechanical ventilation, while no effect on hospital mortality and functional outcome. Clinicians should be aware of the distinctive characteristics and treatment options of PSH in severe anti-NMDARE.
Identifiants
pubmed: 33912193
doi: 10.3389/fimmu.2021.665183
pmc: PMC8072271
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
665183Informations de copyright
Copyright © 2021 Wang, Su, Tan, Wu and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Head Trauma Rehabil. 2017 Sep/Oct;32(5):E50-E54
pubmed: 28060200
Case Rep Neurol Med. 2016;2016:7967526
pubmed: 27190663
J Neurotrauma. 2012 May 1;29(7):1364-70
pubmed: 22150061
Pacing Clin Electrophysiol. 2013 Mar;36(3):e90-2
pubmed: 21671956
Neurol Sci. 2016 Dec;37(12):1993-1998
pubmed: 27620725
J Crit Care. 2019 Feb;49:110-117
pubmed: 30415180
BMC Neurol. 2019 Jul 17;19(1):162
pubmed: 31315589
Med Hypotheses. 2008;70(1):26-35
pubmed: 17583440
J Trauma. 2006 Nov;61(5):1129-33
pubmed: 17099518
Brain Res. 2020 Jan 15;1727:146549
pubmed: 31726044
J Int Med Res. 2020 Oct;48(10):300060520925666
pubmed: 33100078
Lancet Neurol. 2017 Sep;16(9):721-729
pubmed: 28816118
J Neurotrauma. 2014 Sep 1;31(17):1515-20
pubmed: 24731076
Brain Inj. 2007 Oct;21(11):1175-81
pubmed: 17952716
J Neurotrauma. 2021 Apr 13;:
pubmed: 18771395
Clin Auton Res. 2013 Apr;23(2):109-11
pubmed: 23229019
J Neurol Neurosurg Psychiatry. 1999 Jul;67(1):39-43
pubmed: 10369820
Brain Inj. 2015;29(4):455-61
pubmed: 25565392
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
J Neurosci. 2010 Apr 28;30(17):5866-75
pubmed: 20427647
Acta Neurochir (Wien). 2016 Nov;158(11):2047-2052
pubmed: 27581717
Anesth Analg. 2011 Nov;113(5):1188-91
pubmed: 21918158
J Neurotrauma. 2010 Nov;27(11):1945-50
pubmed: 21028988
Curr Treat Options Neurol. 2008 Mar;10(2):151-7
pubmed: 18334137
Ann Neurol. 2010 Aug;68(2):126-35
pubmed: 20695005
Eur J Neurol. 2010 Sep;17(9):1172-7
pubmed: 20298427
J Neurotrauma. 2019 Aug 15;36(16):2430-2434
pubmed: 30887860
Brain Inj. 2018;32(9):1115-1121
pubmed: 29856656